Publications by authors named "M Schostak"
Blunt abdominopelvic trauma frequently results in injuries to the urinary organs, especially in polytrauma. The urotrauma is rarely an acute life-threatening event; however, it may lead to severe complications. This review addresses the under-representation of urological trauma management in interdisciplinary medical training and its impact on patient outcomes.
View Article and Find Full Text PDFArticle Synopsis
- The CABASTY study investigated the effects of biweekly administration of a lower dose of cabazitaxel on pain and quality of life for older men with metastatic castration-resistant prostate cancer (mCRPC).
- In a trial involving 196 patients, researchers compared biweekly dosing (16 mg/m) to a standard triweekly dosing (25 mg/m) regarding pain progression and health-related quality of life (HRQoL).
- Results showed no significant differences in pain progression or HRQoL between treatment groups, but the biweekly group experienced a delayed onset of some adverse events, suggesting it could be a safer option for older patients.
Importance: Studies with nivolumab, an approved therapy for metastatic urothelial carcinoma (mUC) after platinum-based chemotherapy, demonstrate improved outcomes with added high-dose ipilimumab.
Objective: To assess efficacy and safety of a tailored approach using nivolumab + ipilimumab as an immunotherapeutic boost for mUC.
Design, Setting, And Participants: In this phase 2 nonrandomized trial, patients with mUC composed 2 cohorts.
Objective: To demonstrate the added benefit of multiparametric (mp)MRI risk stratification during active surveillance.
Methods: This prospective, single-arm, nonrandomized study included 82 men with low-risk prostate cancer (PCa). We compared two biopsy strategies in parallel.
Purpose: To determine oncological and functional outcomes and side effects after focal therapy of prostate cancer (PCa) with high-intensity focused ultrasound (HIFU).
Methods: This retrospective single-center study included 57 consecutive patients with localised PCa. Aged 18-80 with ≤2 suspicious lesions on mpMRI (PIRADS ≥ 3), PSA of ≤15 ng/mL, and an ISUP GG of ≤2.